60 Avenue Rockefeller
69008 Lyon France
September 28, 2021
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Laura Crotty
| Re: | ERYTECH Pharma S.A. |
Registration Statement on Form F-3
Filed September 21, 2021
File No. 333-259690
Acceleration Request
Requested Date: September 29, 2021
Requested Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form F-3 (File No. 333-259690) (the “Registration Statement”) to become effective at 4:00 p.m. Eastern Time on September 29, 2021, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Britt Eichner of Cooley LLP, counsel to the Registrant, at (617) 937-2362.
[Signature page follows]
Very truly yours,
ERYTECH PHARMA S.A.
| By: | /s/ Eric Soyer | |
| Eric Soyer | ||
| Chief Financial Officer, Chief Operating Officer and Deputy General Manager |
| cc: | Gil Beyen, ERYTECH Pharma S.A. |
Marc A. Recht, Cooley LLP
Brian F. Leaf, Cooley LLP
Courtney T. Thorne, Cooley LLP
Britt Eichner, Cooley LLP
Arnaud Duhamel, Gide Loyrette Nouel A.A.R.P.I.
Guilhem Richard, Gide Loyrette Nouel A.A.R.P.I.